An official website of the United States government
          Here’s how you know
        Here’s how you know**Official websites use .gov**A
              **.gov** website belongs to an official government
              organization in the United States.
        **Secure .gov websites use HTTPS**A
              **lock** (
              Locked padlock icon) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
 Top Utility Nav
        
        
        Asian-Language Resources
        
        Portal en español


Site search Mega Menu
  

        

        Home
                  Health Topics
                                      
    
  Health Topics

    Arthritis and Rheumatic Diseases
          
    Muscle and Bone Diseases
          
    Skin Diseases
          
    All Diseases and Conditions
          
    Publication Catalog
                  Grants & Funding
                                      
    
  Grants & Funding

    Current Funding Opportunities
          
    Supported Scientific Programs
          
    NIAMS-Supported Programs
          
    Applying for a Grant
          
    NIH Policies and Guidance
          
    Peer Review and Grants Administration Resources
          
    Types of Funding Mechanisms (Activity Codes)
                  Labs @ NIAMS
                                      
    
  Labs @ NIAMS

    NIAMS Labs and Core Facilities
          
    Research Faculty
          
    Research Areas
          
    NIAMS Scientific Advances
          
    Training and Career Development
                  Clinical Trials
                                      
    
  Clinical Trials
      
            For Principal Investigators

    Clinical Trial Policies, Guidelines, and Templates
          
    Conducting Clinical Trials
          
    Register with ClinicalTrials.gov

For Patients

What is a Clinical Trial?
	Clinical Trials at NIAMS
	Clinical Trials in the Spotlight
                  News & Events
                                      
    
  Newsroom

    All NIAMS News
          
    NIAMS Newsletters
          
    Meetings & Events
                  About NIAMS
                                      
    
  About NIAMS

    Director's Page
          
    NIAMS Organization
          
    Strategic Plan Fiscal Years 2020-2024
          
    Staff Directory
          
    NIAMS Budget
          
    Partnerships
          
    Contact NIAMS
                  Community Outreach
                                      
    
  Community Outreach

    Bone Health
          
    Joint Health
          
    Muscle, Tendon, and Ligament Health
          
    Skin Health
          
    Health Information For Kids And Young Adults
          
    Health Information For Older Adults/Seniors
          
    Printable Materials for Community Events
          
    Resources in Other Languages
          
    Annual Health Observances
          
    Social Media Resources Breadcrumb
    Home
          Grants & Funding: The NIAMS Extramural Program
          NIAMS Funding Opportunities
          NIAMS Concept Clearances








NIAMS Concept Clearances *January 30, 2024*
      FacebookEmailPrintFacebookEmail 
    NIAMS extramural staff continually work to identify critical research opportunities and needs within our mission area. When identified, NIAMS program officers recommend *concepts*, which describe the basic purpose, scope, and objectives of a potential initiative that NIAMS may wish to pursue. *Concept clearance* is the planning process that begins approximately two years prior to any potential funding. Through this process, NIAMS receives input from the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council (NAMSAC) regarding the merits of proposed research concepts. Concepts presented to the Council are posted here to alert researchers to NIAMS research interests and potential funding opportunities.January 30, 2024August 29, 2023June 6, 2023January 31, 2023August 31st, 2021May 18, 2021January 26, 2021September 1, 2020June 9, 2020June 5, 2019February 5, 2019Past Concept Clearances
      
        
      October 2204
              January, 2024
              NIAMS Clinical Trial Program
      
  

    
      The goal of the NIAMS Clinical Trial (CT) Program is to prevent or reduce symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal or skin diseases. The purpose of this initiative is to foster clinical trials that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these diseases. Awards funded under this initiative would support implementation of investigator-initiated clinical trials and observational studies. Applicants would be required to have completed necessary planning activities prior to submission. NIAMS expects supported trials will address highly significant clinical questions with the potential for impact, and be hypothesis driven, milestone-defined, and within the research mission of the NIAMS.
              August 29, 2023
              Integrated Research on Mechanisms of Pain
      
  

    
      To address musculoskeletal and peripheral pain as integrated processes with certain shared functions.Different initiatives will be managed as part of this integrated program.Individual initiatives will be formulated through programmatic input and insight to address gaps in knowledge and identify novel research directions.
              June 6, 2023
              Accelerating Interoperable Data Ecosystem (AIDE)
      
  

    
      The ultimate goal is to use the data resources being generated by the Accelerating Medicines Partnership (AMP) programs (and other NIH big data initiatives), to establish a knowledge network for a molecular taxonomy of disease enabled by open science practices and data interoperability so that each patient is understood and treated on the basis of the pathways causing disease as well as the clinical manifestations.
      The Exposome in Autoimmune Diseases Collaborating Teams (EXACT)
      
  

    
      Human diseases often result from complex interactions between patients’ genetic susceptibilities and environmental exposures (exposome). Few such interactions have been systematically examined in autoimmune diseases (AID), and the role of the exposures and the biological responses that they generate in disease initiation and progression remains largely unknown. Significant research gaps include elucidation of how the exposome affects the heterogenous molecular and cellular pathways leading to autoimmunity, and novel approaches to avoid or neutralize interactions that might contribute to AID. Using AID as an example, the proposed EXACT program is expected to provide a basis for future studies on the exposome’s role in other health conditions.
      Research Innovations for Scientific Knowledge (RISK) Initiative
      
  

    
      The RISK initiative is designed to capture and test novel and audacious ideas in their early stage of development, which may be less likely than more conventional proposals to be funded using traditional NIH funding mechanisms.
              January 31, 2023
              Accelerating Research in Non-White Skin Types
      
  

    
      This initiative aims to promote research uncovering the basis for inferior diagnosis, increased prevalence, elevated clinical severity, and altered treatment response in skin diseases in African Americans (AA), Asian Americans and Pacific Islanders (AAPI), American Indians/Alaska Natives (AI), and non-white Hispanics (NWH) populations.
      Supplements to Advance Research (STAR) from Projects to Programs
      
  

    
      The STAR Program is intended to promote innovation and exploration of high-risk ideas by providing supplemental funding to early-career investigators. It will support activities that effectively allow these investigators to expand and explore new opportunities within the broader scope of a currently funded, peer-reviewed research project to facilitate the transition from a single, structured research project to a broader multi-faceted research program.
              August 31st, 2021
              Mapping Neurons to Understand Mechanisms of Joint Pain
      
  

    
      The goal of the initiative is to support research aimed at three-dimensional, global mapping of the sensory nerve terminals in the different tissues of the joint. This would include tracking changes in innervation with aging and other factors, including changes that occur in arthritis. This project is expected to lead to the translation of research on nerves and mediators into finding new inhibitors of pain.
      Collaborative Research in Chronic Pain
      
  

    
      The goal is to advance the understanding of mechanisms of pain in adults and children in disease areas within the NIAMS mission. The initiative is designed to support basic, clinical, and translational projects that integrate precision medicine approaches to address significant challenges in prevention, treatment and health equity in chronic pain. These may require a highly collaborative research infrastructure with the participation, interaction and coordination of activities carried out across multiple research laboratories and disciplines. The projects are expected to generate research resources to be shared with the community and foster discovery-based or hypothesis-generating science.
              May 18, 2021
              January 26, 2021
              NIAMS Disease Profiling Initiative
      
  

    
      The NIAMS is proposing an interdisciplinary disease profiling initiative that will better allow for large, interdisciplinary team approaches to deepen our understanding of individual musculoskeletal, rheumatic, and skin diseases.  Research teams would be brought together to use unique combinations of innovative techniques, technologies, and analytical methods that could ultimately lead to better phenotyping of disease and discoveries that could impact design and targeting of future therapies.
              Promoting a Basic Understanding of Chemical Threats to Skin
      
  

    
      Developing countermeasures against chemical attacks to the civilian population is a major goal of the civilian defense program at NIH, of which the Chemical Counter-measures Research Program (CCRP) is a part.  NIAMS has been one of several ICs participating in the CCRP since its inception in 2006. In order to broaden its research base and raise awareness of the research community at large about the urgent need for countermeasures against terrorist attacks using chemical agents, the CCRP is encouraging its participating ICs to issue IC-specific FOAs to reach out to the respective research disciplines that were not engaged previously in the countermeasure research.  This initiative is a response to that request. The goal of the initiative is to encourage the NIAMS skin research community to contribute to the basic understanding of injuries caused by toxic chemicals and to explore the local and systemic mechanisms of chemical wound development, healing, and long-term consequences.  An emphasis is on understanding the commonalities of injuries caused by a variety of chemical toxins and identifying potential shared therapeutic targets, which could be used for developing broad spectrum countermeasures.
              September 1, 2020
              Accelerating Medicines Partnership Program in Autoimmune and Immune-Mediated Diseases (AMP AIM)
      
  

    
      Over the last 6 years, the Accelerating Medicines Partnership – rheumatoid arthritis and systemic lupus erythematosus (AMP RA/SLE) program has brought together public and private communities to make unprecedented progress in understanding the molecular and cellular mechanisms that cause these diseases. AMP RA/SLE program has advanced the concept of disease deconstruction by establishing the value and feasibility of using high dimensional, single cell analytics on biopsy samples taken from tissues of patients with RA or lupus to discover novel cell populations and pathways active in the diseased tissues and to identify promising targets for drug development.The goal of the new phase – AMP Autoimmune and Immune-mediated Diseases (AMP AIM) – will be to extend disease deconstruction and mapping of cells and pathways in RA, lupus, to include Sjogren’s syndrome and psoriasis/psoriatic arthritis. The cornerstone of AMP AIM will be the concept of disease reconstruction based on high dimensional study of cell interactions. AMP AIM will not only refine and extend the single cell analysis of tissues to other autoimmune diseases (disease deconstruction), but will also bring in high dimensional novel analytics to discover how innate and adaptive cells of the immune system and tissue resident cells network with each other to cause inflammation, injury, abnormal function and clinical disease (disease reconstruction). Integration of these multi-modality data will accelerate the discovery of new mechanisms of disease and new targets for therapeutic development.
              June 9, 2020
              Exploring New Mammalian Models for Studying Tissue Regeneration
      
  

    
      This initiative aims to promote research exploring new mammalian models with naturally high regenerative capacity such as the African spiny mice or naked mole rat. It is expected to facilitate basic studies focused on the discovery of previously unidentified developmental paradigms and delineation of key cellular and molecular mechanisms that should help provide therapeutic targets for the development of future regenerative therapies.
      Role of Inflammation Resolution in Chronic Inflammatory Diseases within NIAMS Mission
      
  

    
      This initiative promotes research on resolution of inflammation, which is a complex and distinctively coordinated response from the onset of inflammation. Uncontrolled and dysfunctional resolution of inflammation would directly link to chronic inflammation, a common pathogenic element among diseases within the NIAMS core mission. Therefore, unraveling basic, translational, and pre-clinical mechanisms of inflammation resolution would contribute significantly to the understanding of pathogenesis and the development of innovative therapies for chronic inflammatory diseases within the NIAMS mission.
      Accelerating Host Gene-Microbiome Interactions Research in NIAMS Core Mission Diseases
      
  

    
      Host genetics, (i.e. the description of polymorphism at the level of non-coding risk loci or disease causal genes), and the diversity of the gut and/or the skin microbiome, have both been considered to be important contributing factors to a variety of pathologies. However, they are usually considered as independent contributors, and their synergism is poorly understood. Defining the synergism between the host genetics and the diversity and composition of the microbiome may be key to progress in the understanding of the pathogenesis of many diseases and conditions supported by the NIAMS. This initiative proposes to accelerate research focused on describing how host gene-microbiome interactions may impact diseases and conditions within NIAMS mission.
      Evidence, Challenges and Lessons Learned in Clinical Trials of Cell-based Therapies for Knee Osteoarthritis
      
  

    
      This initiative proposes a scientific conference to engage a diverse group of stakeholders, including thought leaders in the orthopaedic research and clinical communities, clinical investigators who have conducted or are currently conducting cell-based OA clinical trials, and the FDA to discuss and share knowledge gained through these trials.
      Addressing Health Equity in OA
      
  

    
      There is evidence of differential OA treatment outcomes and access to care in diverse populations, which lead to poor health. This concept is a placeholder for development and implementation of recommendations from a “state of the science” workshop of OA that would be similar to but smaller scale than the NIH P2P workshops. The underlying premise of the P2P workshop, which seeks to move a public health issue forward after a detailed, unbiased, evidence-based assessment of the current scientific research, will be followed. The proposed workshop would provide a snapshot of the current issues, particularly surrounding disparities and access to health care. The goal is to identify research gaps/needs that could be addressed in future NIAMS activities. NIAMS intends to implement these activities in collaboration with other NIH Institutes, Centers, and Offices and federal agencies.
      Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers
      
  

    
      The purpose of this initiative is to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. These Centers promote collaborative basic, translational, and clinical research, and provide important resources that can be used by the national muscular dystrophy research community. The Centers also provide outstanding environments for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Furthermore, Center investigators participate in community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.
      Core Centers for Clinical Research (CCCR)
      
  

    
      The CCCRs provide avenues to advance the methodological sciences that support clinical research within and across the NIAMS' portfolio of diseases. The overall goals of the CCCR are to advance prevention, diagnosis and treatment of musculoskeletal, rheumatic, and skin diseases by developing and fostering the implementation of novel methods, metrics, and outcome measures that address critical existing and emerging clinical research needs.
      NIAMS Clinical Studies Operations Management and Support Contract
      
  

    
      This initiative will provide essential clinical research operations management, resources and services using a highly skilled contract research organization (CRO) for NIAMS funded clinical research studies. This mechanism allows the Institute to meet its responsibility for providing oversight functions to ensure the safety of participants and quality of data generated from clinical studies it supports.
              June 5, 2019
              Translation of Biomedical and Behavioral Research Results from Academic/Non-profit Lab to Marketplace (R43/R44)
      
  

    
      This initiative will solicit Small Business Innovation Research grant applications from small business concerns that propose research and development studies to facilitate translation of lab discoveries from academic or non-profit institutions to marketplace to advance the diagnosis, treatment, and prevention of musculoskeletal, rheumatic or skin diseases.
      Accelerating Discovery in NIAMS Studies with Computational Models, Tools, and Workflows
      
  

    
      This initiative will explore opportunities to accelerate research in rheumatic, musculoskeletal, and skin diseases through the development, validation, and adoption of computational models, tools, and workflows.  A variety of mechanisms will be used to seek community input, integrate responses with feedback from the strategic plan listening sessions, and to inform next steps.
      Roundtable on Neurogenic Inflammation Research: Gaps and Opportunities
      
  

    
      Experimental evidence indicates that the functions of the immune and peripheral nervous systems are connected, yet the cellular and molecular mechanisms by which these systems communicate, are not fully elucidated. It is critical to fully understand the mechanisms by which sensory and autonomic signals regulate different types of immune cells at baseline and during inflammation and autoimmunity. As a result, NIAMS proposes to conduct a roundtable to identify important scientific opportunities, barriers, knowledge gaps and research needs in neurogenic inflammation research as related to NIAMS mission relevant research.
      Advancing Research on Drug Therapies for Fracture Prevention
      
  

    
      This initiative is a placeholder for implementing recommendations from the NIH Pathways to Prevention workshop on Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention. NIAMS intends to implement these activities in collaboration with other NIH ICOs and federal agencies.
      NIAMS Clinical Trial Roundtable: Who to Treat When with What
      
  

    
      The goal of this proposed roundtable is to gather information from the NIAMS research communities to inform the NIAMS on the best trial designs to conduct research that informs clinical care. The discussions from this meeting will focus on understanding the fit between different trial designs, the intervention, and outcomes and how the evidence generated from trials influence various stakeholders in their decision-making.
      Resource-based Centers for Rheumatic Diseases Research and Resource-based Centers for Musculoskeletal Biology and Medicine
      
  

    
      Centers supported under these funding opportunity announcements will focus on developing and providing access to research resources.
      Centers of Research Translation (CORT)
      
  

    
      The goal of this continuation of the CORT Program is to foster translational research, directed at elucidating the relevance of basic research to human disease in an area within the NIAMS mission. A CORT must have a minimum of three highly meritorious research components consisting of one or more translational Research Projects and one or more Research Cores. Using an investigative team science approach, the projects and cores will enable the generation of new knowledge that
      NIAMS Clinical Trial Implementation Cooperative Agreement
      
  

    
      Awards funded under this initiative would support implementation of investigator-initiated clinical trials where applicants would be required to have completed necessary planning activities. NIAMS expects supported trials will address highly significant clinical questions with the potential for impact, and be hypothesis driven, milestone-defined, and within the research mission of the NIAMS.
      Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases
      
  

    
      The purpose of the Exploratory Clinical Trials Grants Program is to foster clinical trials that can be completed within a limited timeframe and budget, and that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of NIAMS core mission diseases. Awards funded under this initiative support and facilitate clinical trials that can be completed within a limited timeframe and budget.
      Clinical Observational Studies (COS) in Musculoskeletal, Rheumatic, and Skin Diseases
      
  

    
      Awards funded under this initiative would support clinical observational studies to obtain information that is necessary for designing clinical trials for musculoskeletal, rheumatic, or skin diseases or conditions. Applicants will be required to justify the need for the observational study in preparing for a future trial or trials. Applications may include characterization of cohorts similar to potential future trial participants and collection of data to justify the use of a biomarker or a patient outcome measure in a future trial. Applications for early stage development of new biomarkers or outcome measures, studies of disease mechanisms or pathophysiology, and therapeutic target identification will not be responsive to this initiative unless the resulting data is necessary for designing a clinical trial in the near term. This initiative will only support observational studies and will not support intervention studies.
              February 5, 2019
              Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases
      
  

    
      This initiative would encourage Small Business Innovation Research grant applications from small business concerns that propose translational studies to advance the development of products for diagnosis, treatment, and prevention of rare musculoskeletal, rheumatic or skin diseases.
      Mechanistic Ancillary Studies to Ongoing Clinical Projects
      
  

    
      This initiative would encourage applications that propose time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with ongoing clinical projects. The ongoing “parent” project would have to be a clinical study that can provide a sufficient cohort of well-characterized patients, infrastructure, data, and biological samples. Applications submitted in response to this initiative would undergo an accelerated review and award process.
      Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients
      
  

    
      This initiative would continue the NIAMS small grant program for investigators to develop preliminary data for their first R01 application. The program would provide NIAMS-supported K08 and K23 recipients the opportunity to apply for  support in the second to fourth year of their K awards.
      NIAMS Clinical Trial Planning Grant
      
  

    
      This initiative would provide the necessary administrative and planning support for investigator-initiated clinical intervention clinical trials. Completion of the required milestones of a planning grant are a prerequisite for acceptance of a U01 clinical trial application, which supports the implementation and conduct of the study. Consultation with NIAMS staff would continue to be strongly encouraged prior to the submission of the planning grant application.
              Past Concept Clearances
              Archives
      
  

    
      **Council Year****Initiative****Description**Sept 5, 2018NIH Back Pain Consortium (BACPAC) Research ProgramThe NIH **Bac**k **Pa**in Research **C**onsortium (BACPAC) is a potential initiative to address opioid addiction. BACPAC is a patient-centric translational research program that will address the need for effective and personalized therapies for chronic low back pain by probing the biomedical mechanisms in a biopsychosocial context using interdisciplinary methods and innovative technologies.Back pain is a major contributor to the use of opioids in the U.S., however, at present no effective treatment exists that provides long term, sustained relief of back pain and disability for all patients. Further, there is no way to predict what treatments are most likely to be effective in individual patients. This initiative will foster development of integrated models of back pain to improve understanding of the condition and generate new tools for better targeting of existing and new therapies.Sept 6, 2017Clinical Observational Studies (COS) in Musculoskeletal, Rheumatic, and Skin Diseases Re-IssueThis initiative will support clinical observational studies to obtain information that is necessary for designing clinical trials for musculoskeletal, rheumatic, or skin diseases or conditions. Data obtained through the studies may also have a direct impact on clinical care. Applications can include characterization of cohorts similar to potential future trial participants and collection of data to justify the use of a biomarker or a patient outcome measure in a future trial. Researchers must explain how the data they propose to collect could contribute to the design of a clinical trial or trials in the near term. This initiative will emphasize the collection of data that addresses significant obstacles to the design of a clinical trial or trials. Applicants will be required to justify the need for the observational study in preparing for a future trial or trials.This initiative will improve understanding of diseases and conditions within the NIAMS mission. Research data from observational cohort studies can enhance clinical trial design by providing essential information about disease symptoms, stages and timing of disease progression, comorbid conditions, availability of potential clinical trial participants, and outcomes that are important to patients. Clinical observational studies also can facilitate efforts to validate and eventually qualify objective biomarkers or subjective outcome measures for use in future trials or in the clinical care setting.Sept 6, 2017Core Centers for Clinical Research (CCCR) Re-IssueThe CCCRs provide avenues to advance the methodological sciences that support clinical research within and across the NIAMS' portfolio of diseases. The overall goals of the CCCR are to advance prevention, diagnosis and treatment of musculoskeletal, rheumatic, and skin diseases by developing and fostering the implementation of novel methods, metrics, and outcome measures that address critical existing and emerging clinical research needs.This initiative builds on emerging thinking and innovative ideas, such as the surge in 'omics' data, enabling these new approaches to ultimately improve health-related outcomes for patients with musculoskeletal, rheumatic, or skin diseases or conditions.Sept 6, 2017Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases Re-IssueThis initiative would address the need to support and facilitate clinical trials that can be completed within a limited timeframe and budget. A broad range of types of exploratory studies are suitable for this initiative. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies.This initiative will improve understanding of diseases and conditions within the NIAMS mission by fostering clinical trials that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these diseases.Sept 6, 2017Mechanistic Ancillary Studies to Ongoing Clinical Projects Re-IssueThis initiative would leverage the existing resources offered by already-funded clinical studies, and maximize the return on the public investment. Successful ancillary studies would enhance the scientific content and value of the parent studies, improve our understanding of the underlying mechanisms of diseases in the NIAMS portfolio, and thus identify novel targets for the diagnosis, treatment, and prevention of disease.Clinical studies, ranging from epidemiological observational studies to clinical trials, play a valuable role in carrying out the mission of the NIAMS. Large clinical projects offer unique opportunities to conduct additional investigations that go beyond the core activities of the original study and generate new information related to the original study.Sept 6, 2017Research Innovations for Scientific Knowledge (RISK) Initiative Re-IssueThe NIAMS RISK initiative is an effort to encourage and facilitate innovative research in NIAMS-supported communities. It is designed to capture and test novel and audacious ideas in their early stages of development, which may be less likely than more conventional proposals to be funded using traditional NIH funding mechanisms.The initiative provides a way for the Institute to encourage highly innovative research and to accelerate testing of high-risk and high-impact ideas. The research funded through RISK has the potential to produce breakthroughs or paradigm shifts that improve public health or launch new fields of scientific inquiry.Sept 6, 2017Resource-based Centers Re-Issue - Musculoskeletal Biology and MedicineThe overall goal of the NIAMS Resource-based Centers program is to promote a cooperative interaction among basic science and/or clinical investigators in a manner that will enrich the effectiveness of ongoing research and promote new research. For these Musculoskeletal Biology and Medicine Resource-based Centers, the emphasis will be on improving access to resources. This includes the potential for either resources or investigators to be distributed at different institutions, particularly for technical resources that do not need to be duplicated at every institution. Shared resource cores could be typical core facilities, or may provide access to unique expertise or services, such as epidemiology, outcomes, genetics, or informatics, which may be necessary to address a common problem.Musculoskeletal Biology and Medicine Resource-based Centers enable research that should advance understanding of human disease and promote the discovery of the causes, treatment and prevention of musculoskeletal diseases.Sept 6, 2017Resource-based Centers Re-Issue - Skin Biology and DiseasesThe overall goal of the NIAMS Resource-based Centers program is to promote a cooperative interaction among basic science and/or clinical investigators in a manner that will enrich the effectiveness of ongoing research and promote new research. For these Skin Biology and Diseases Research Resource-based Centers, the emphasis will be on improving access to resources. This includes the potential for either resources or investigators to be distributed at different institutions, particularly for technical resources that do not need to be duplicated at every institution. Shared resource cores could be typical core facilities, or may provide access to unique expertise or services, such as epidemiology, outcomes, genetics, or informatics, which may be necessary to address a common problem.Skin Biology and Disease Research Resource-based Centers enable research that should advance understanding of human disease and promote the discovery of the causes, treatment and prevention of skin diseases.Sept 6, 2017Supplements to Advance Research (STAR) from Projects to Programs Re-IssueThe objective of the NIAMS STAR Program is to promote innovation and exploration of high-risk ideas by providing supplemental funding to early established investigators (EEIs). The STAR Program supports activities that effectively allow EEIs to expand and explore new opportunities within the broader scope of a currently funded, peer-reviewed research project to facilitate the transition from a single, structured research project to a research program.This initiative will contribute to NIAMS efforts to support promising investigators as they develop robust research programs.Sept 6, 2017Translational Research in Hidradenitis SuppurativaEncouraging pre-clinical research on hidradenitis suppurativa (HS) through this initiative has the potential to lead to a better understanding of the pathogenesis and genetics of the disease, as well as define several potential novel targets for repurposing of available drugs or development of new treatments. HS is a complex chronic inflammatory skin disease characterized by recurrent painful nodules and suppuration in different areas of the body such as the axilla and groin.There is no biological or pathological test to diagnose HS, which is defined only by its clinical features. HS is known to affect three-times more women than men, and is more prevalent among minorities (e.g., African Americans). Disease pathogenesis is poorly understood and available treatments are limited. 
    FacebookEmailPrintFacebookEmail
 About NIAMS
                    Clinical Trials
                    Grants & Funding
                    Health Topics
                    Labs @ NIAMS
              News Room
                    NIAMS Multimedia Library
                    Disclaimer
                    FOIA
                    Contact us
              Privacy Statement
                    Accessibility
                    HHS Vulnerability Disclosure
                    Social Media Moderation Policy
                    NIAMS Archives
        Subscribe to Our E-Newsletters
            Click the button to see different options to sign up for newsletters.
            Click Here to Subscribe
          Follow us on
  
  About NIH
                  Accessibility Support
            FOIA requests
                  No FEAR Act data
            Office of the Inspector General
                  Performance reports
            Privacy Policy Back to Top